Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action by Ralph, Stephen John
Hindawi Publishing Corporation
Metal-Based Drugs
Volume 2008, Article ID 260146, 13 pages
doi:10.1155/2008/260146
ReviewArticle
Arsenic-Based Antineoplastic Drugs and
Their Mechanisms of Action
Stephen John Ralph
School of Medical Sciences, Griﬃth University, Parklands Drive, Southport, Queensland 4215, Australia
Correspondence should be addressed to Stephen John Ralph, s.ralph@griﬃth.edu.au
Received 1 April 2007; Revised 3 July 2007; Accepted 17 August 2007
Recommended by Rafael Moreno-Sanchez
Arsenic-based compounds have become accepted agents for cancer therapy providing high rates of remission of some cancers such
as acute promyelocytic leukemia (APL). The mechanisms by which arsenic-containing compounds kill cells and reasons for selec-
tive killing of only certain types of cancer cells such as APLs have recently been delineated. This knowledge was gained in parallel
with increasing understanding and awareness of the importance of intracellular redox systems and regulation of the production of
reactive oxygen species (ROS) by controlling mitochondrial function. Many of the targets for the arsenic-containing compounds
aremitochondrialproteinsinvolvedinregulatingtheproductionofROS.Inhibitionoftheseproteinsbydisulﬁdelinkageofvicinal
thiol groups often leads to increased production of ROS and induction of apoptotic signalling pathways. Sensitivity or resistance
to the actions of arsenic-containing compounds on cancer cells and normal cells depends on the levels of transport systems for
t h e i ru p t a k eo re ﬄux from the cells as well as their redox defence mechanisms. The exact mechanisms of arsenic toxicity as well as
its anticancer properties are likely to be related and these aspects of arsenic metabolism are covered in this review. Greater under-
standing of the mechanisms of action of arsenic will help determine the risks of human exposure to this chemical. Novel organic
arsenic-containing compounds and the lessons learned from studying their selective sensitivity in targeting dividing endothelial
cells to inhibit angiogenesis raise the future possibility for designing better targeted antineoplastic arsenic-containing compounds
with less toxicity to normal cells.
Copyright © 2008 Stephen John Ralph.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. ARSENIC AND ARSENIC-CONTAINING
COMPOUNDS IN THE NATURAL ENVIRONMENT
OR AS A RESULT OF HUMAN APPLICATION
Arsenic is a toxic metalloid [1, 2] that exists throughout na-
ture in organic and inorganic forms. It is commonly present
in soils on average at several mg/kg, as well as in marine
sediments, and is enriched in mineral deposits as oxides
and sulﬁdes. The basic element, arsenic, exists in either of
three allotropic forms: yellow, black, or grey with the stable,
semimetallic formhaving a silver/steely-grey colouras a brit-
tle, crystalline solid. The semimetallic form oxidises rapidly
in air, and at high temperatures produces a white cloud of
arsenic trioxide (As2O3). Arsenic, with its variety of chemi-
cal forms and oxidation states, is listed in Table 1.T h ec u r -
rent IUPAC nomenclature is listed in [3]a sw e l la st h em o r e
common names of the arsenic-based compounds which are
mainly used throughout this review.
When absorbed at toxic levels, arsenic causes severe
health problems, including cancer. Acceptable levels were
lowered from 50μg/L to 10μg/L in drinking water by the
WHO [4]. Arsenic-containing compounds are applied in
plant pesticides and insecticides and arsenic environmental
contamination represents a global health problem, particu-
larly from leaching into ground water. When the soluble lev-
els exceed 50μg/L in drinking water as in many regions of
Bangladesh, arsenic becomes a particular health concern as
it has recently been associated with increased cancer rates
appearing after consumption with a lag time up to 10–20
years [5].
Whilst the carcinogenic aspects of arsenic compounds
are not the focus of this review, nevertheless this undesirable
aspect needs to be raised. Thus, arsenic and its methylated
species are known carcinogens but this description is proba-
bly inaccurate as they act more as cocarcinogens by facilitat-
ing/promoting the induction of tumors of the skin, urinary2 Metal-Based Drugs
Table 1: Common names and fully systematic (additive) names for Arsenic oxoacid and related structures. Some organic derivative names
still contain the word “acid,” as in the following derivatives of arsonic acid = H2AsHO3 = [AsHO(OH)2], for example,P h A s O ( O H ) 2 pheny-
larsonic acid.
Example of alternative names for Arsenic species used
Common name Abbreviation IUPAC Fully systematic additive name Chemical formula
Arsenite, Arsenous acid, Arsorous acid As(III), AsIII Trihydroxidoarsenic H3AsO3 = [As(OH)3]
Arsinious acid As(III), AsIII Dihydrohydroxidoarsenic HAsH2O = [AsH2(OH)]
Arsonous acid As(III), AsIII Hydridodihydroxidoarsenic H2AsHO2 = [AsH(OH)2]
Arsenate, Arsenic acid, Arsoric acid As(V), AsV Trihydroxidooxidoarsenic H3AsO4 = AsO(OH)3
Arsinic acid As(V), AsV Dihydridohydroxidooxidoarsenic HAsH2O2 = [AsH2O(OH)]
Arsonic acid As(V), AsV Hydridodihydroxidooxidoarsenic H2AsHO3 = [AsHO(OH)2]
Monomethylarsonic acid MMA(V), MMAV Methanedihydroxidooxidoarsenic CH3AsO(OH)2
Monomethylarsonous acid MMA(III), MMAIII Methanedihydroxidoarsenic CH3As(OH)2
Dimethylarsinic acid DMA(V), DMAV Dimethanehydroxidooxidoarsenic (CH3)2AsO(OH)
Dimethylarsinous acid DMA(III), DMAIII Dimethanehydroxidoarsenic (CH3)2AsOH
bladder, and lung rather than directly inducing cell trans-
formation and oncogenesis [2, 6]. As cocarcinogens, mech-
anisms include indirect eﬀects such as DNA damaging geno-
toxicity by altered DNA methylation as well as inducing high
levels of oxidative stress leading to altered cell proliferation
and tumor promotion (detailed in [7]).
In terms of chronic toxicity, the 50% lethal dose of
arsenic as arsenic trioxide in mice received by the oral
route varies from 15–48mg/kg, whereas the acute lethal
dose in humans varies from 1–3mg/kg body weight [4].
Despite its toxicity, arsenic has been applied in Chinese
medicines for thousands of years as reﬁned preparations of
realgar (As4S4) or orpiment (As2S3)[ 8]w h i c ha r et w or a r e
mineralised forms. Realgar, easily discerned by its bright
red and orpiment with a browny yellow appearance are
ores often occurring close to each other in hydrothermal
veins of precious metal sulﬁde ores or hot spring deposits
as volcanic sublimate products (crystallized from gases).
Hence, arsenic is a common waste product from the min-
ing of metal ores and the name realgar is possibly de-
rived from Arabic words for “powder of the mine” (rahj al
ghar).
The long history of medical applications has included
treating many diseases such as cancers administering mi-
cromolar levels in patients and, in particular, arsenic com-
poundshaveproventobeveryeﬀectiveagainstcertainhema-
tological malignancies (reviewed in [9, 10]). Thus, arsenic
oxidesandderivativeshavebeenestablishedaseﬀectivetreat-
ments for acute promyelocytic leukemia (APL), and they are
being tested as therapies for a range of other hematologi-
cal cancers including myelodysplastic syndromes, multiple
myeloma, and chronic myelogenous leukemia (CML). The
results of clinical trails using arsenic-based drugs in cancer
therapy have been extensively reviewed [8–12]. Hence, this
review mainly concerns those factors that explain the anti-
neoplastic mechanism of action of arsenic-based drugs, dis-
tinguishing their selectivity for killing certain types of cancer
cells from their potential for toxicity to normal cells in the
body. The reason for their eﬃcacy and selectivity in treat-
ing certain hematological malignancies is covered in the last
section of this review. However, the mechanisms of action of
arsenic-basedcompounds on cells must ﬁrst be described in
detail to provide suﬃcient understanding to enable their se-
lective targeting of speciﬁc types of cancer cells to be duly
evaluated.
Water distributes the majority of inorganic arsenic in
the biosphere either as pentavalent arsenate (As5+, As(V)) or
trivalent arsenic (As3+, As(III) [2]. In solution, the pH and
redox conditions aﬀect the chemical state of arsenic that pre-
dominates.Thus,inhighlyoxidisedenvironments,thearsen-
ate (As5+) form predominates as one of four major species of
arsenicacid;H3AsO4,H 2AsO4
−,HAsO 4
2−,andAsO 4
3− [13].
However, mildly reducing conditions such as those generally
presentinsideallmammaliancells[14]willfavourthereduc-
tionofthepentavalentarsenate(As5+)tothetrivalentarsenic
(As3+). Arsenous acid with the formula As(OH)3 results af-
ter the slow hydrolysis of arsenic trioxide in water. As the pH
increases, arsenous acid is converted to the arsenic oxide ions
[AsO(OH)2]−,[ A s O 2(OH)]−2,a n d[ A s O 3]−3 [13].
2. METHYLATED FORMS OF ARSENIC SHOW
INCREASED CYTOTOXICITY INSIDE CELLS
Arsenic combines readily with many elements; and bacte-
ria have evolved systems to detoxify inorganic arsenic to
form organic arsenic-containing compounds such as methy-
lated forms. Plant and insect pesticides have been made us-
ing organic arsenic derivatives; and monomethylarsonic acid
(MMA(V)) and dimethylarsinic acid (DMA(V)) are used
in products for weed control. Also, MMA(V) and DMA(V)
are metabolites of inorganic arsenic, formed intracellularly
in mammals, primarily in the liver. The metabolic process
of inorganic arsenic conversion is known as biotransforma-
tion and appears to enhance the excretion of arsenic from
the body, involving formation of methylated compounds of
trivalent arsenic as intermediates. The metabolism involves
reduction to a trivalent state and oxidative methylation to
a pentavalent state. In addition, reductases present in cellsS t e p h e nJ o h nR a l p h 3
and other reactions facilitate the reduction of arsenic acid
[As(V)] to the arsenous [As(III)] form including methyla-
tion of the arsenous form, mainly via the liver, to produce
mono-, di-, and trimethylated species [2]. The main en-
zyme involved in methylation of As(III) is arsenic methyl-
transferase(As3MT)that requires glutathione (GSH) to pro-
mote the reaction and a cycling redox system such as thiore-
doxin (reviewed in [15])to detoxify arsenic-containing com-
pounds. Many animal species convert inorganic arsenic-
containing compounds into mono-, di- and tri-methylated
arsenic species which are mostly then secreted in the urine
[16]. This is because the methylated forms are not as well ab-
sorbed by cells compared to the inorganic forms, although
they have much greater cytotoxicity if they do enter cells
[15, 17].
The reductive metabolism of arsenic has an important
role in its toxicity. The trivalent arsenic-containing com-
pounds, including the methylated organic forms have much
greater potency than the pentavalent arsenic-containing
compounds as cytotoxics and carcinogens [18–23]. For ex-
ample, in cytotoxicity assays, the IC50 values for cultures
of primary hepatocytes, keratinocytes, and epithelial cells
rangedfrom3μMt ow ello v e r20μM fortrihydroxidoarsenic
salts whereas for monomethylarsonous acid [MMA(III)],
the values were consistently much lower at only several
μM for the equivalent normal cell types [24–26]. Organic
arsenic-based ingredients are commonly used as feed ad-
ditives in poultry farming to increase weight gain by pre-
venting bacterial and parasitic infections, thereby increas-
ing feed eﬃciency and improving pigmentation. The three
major arsenic-containing compounds used in this man-
ner are arsenilic acid (p-aminophenyl arsonic acid), roxar-
sone (4-hydroxy-3-nitrophenylarsonic acid), and nitarsone
(4-nitro-phenylarsonic acid) [22, 23]. The metabolism of
these arsenic-containing compounds and waste products
produced by birds and mammals consuming them is still un-
certain at present and what the global environmental impact
might be.
3. CELLULAR ACTIONS OF ARSENIC-CONTAINING
COMPOUNDS
3.1. Inhibitorsofenergymetabolism:effectson
glycolysisandoxidativephosphorylation
At the biochemical level, inorganic arsenic in the pentavalent
state (As(V), arsenate, AsO4) resembles a phosphate (PO4)
group in structure and it can replace phosphate in many re-
actions. The mitochondria is a major intracellular site where
arsenate is metabolised, taken up As(V), rapidly reducing it,
and exporting the As(III) product back into the cytosol [27].
The speciﬁc location of the site(s) for arsenic reduction in
the mitochondria has not yet been deﬁned. However, arse-
nate can aﬀect oxidative phosphorylation by binding to the
Fo/F1 ATP synthase [28]. Arsenate can be used by the ATP
synthase more eﬃciently than phosphate depending on the
Ca2+ levels [29], producing ADP-arsenate which unlike ATP
becomes rapidly hydrolysed and unable to form stable high-
energycompounds[30].Itissuggestedthatthestructureand
charge similarities of PO4
3−,A s O 4
3−,a n dS O 4
2− result in in-
discriminate binding to at least two sites located in the mi-
tochondrial matrix [31]. At one site, occupation by any of
these three anions results in protection against uncoupling
of the mitochondrial proton gradient by K+; at the second
site, in the Fo/F1 ATP synthase, AsO4
3− and SO4
2− compete
for binding against PO4
3−, leading to the inhibition of ATP
production [31].
Intriguingly, As2O3, whilst shown to have no eﬀect on
oxidative phosphorylation levels in HeLa [10μM] and AS-
30D [100μM] hepatoma cancer cells, signiﬁcantly inhibited
glycolysis, particularly during the exponential growth phase
of these cells when they were actively respiring and pro-
ducing 70% of their ATP from mitochondria [32]. Several
otherstudieshavealsoshownthatarseniccompoundsdonot
aﬀect oxidative phosphorylation. Thus, with submitochon-
drial particles in the presence of an ATP regenerating system,
20mM arsenate had no eﬀect on NADH formation, ATP hy-
drolysis,andPi←→H20exchange[33].Inarelatedstudywith
isolated liver mitochondria, As2O3 was again shown to have
no eﬀect on oxygen consumption, or the respiratory con-
trol ratio at a concentration (10μM) found to be maximally
eﬀective in promoting apoptosis in whole cells [34]. How-
ever, at higher concentrations (> 50μM), pyruvate/malate-
supported respiration (via complex I) became blocked, but
there was no eﬀect on either complex II or IV. The inhibitory
eﬀect on complex I was reversed by the addition of the re-
ducing agent, dithiothreitol, indicating that direct oxidative
damage was involved. In addition, it was shown that even
with the block in complex I, the cells continued to maintain
cellularATPlevelsthroughglycolysis,andhence,depletionof
cellular ATP was not the cause for the cytotoxicity of As2O3
[34]. Probably the most deﬁnitive evidence for the impor-
tance of mitochondria in mediating As2O3 killing of cancer
cells comes from studying cells lacking mitochondrial func-
tion [35]. A subclone of mitochondrial respiration deﬁcient
cells was derived from the HL-60 human leukaemia cell line
by growth in the presence of ethidium bromide to mutate
the mitochondrial genome, and these cells are known as HL-
60 “ρ0” cells [35]. Due to the lack of mitochondrial respira-
tion, ρ0cells depend on glycolysisfor their energy source and,
as would be expected, produced substantially less superox-
ide radicals (∼20% of the control cells). When these ρ0 cells
were incubated with ∼10μMA s 2O3, they were resistant to
the drug, revealing that mitochondrial respiratory function
is required for the cytotoxic actions of As2O3 [35].
The inhibition of glycolysis by arsenic-based drugs ap-
pears unlikely to be a signiﬁcant factor involved in the drug-
induced killing of cancer cells. Thus, incubating cells in
glucose-deﬁcient medium to block glycolysis had no signif-
icant eﬀect on the As2O
−
3 [30 μM] mediated levels of cell
death in the Jurkat cell line [36]. However, when glycoly-
sis was blocked and mitochondrial respiration inhibited us-
ing oligomycin A, the cells became very sensitive to As2O3−
mediated cell death. In this regard, it is also worth not-
ing that studies of individual glycolytic enzymes analysed
in puriﬁed form in vitro have shown arsenite and arsen-
ate to be relatively weak inhibitors. Hence, for hexokinase
(IC50: 15mM for arsenate [37, 38]), phosphofructokinase4 Metal-Based Drugs
(IC50 > 5mM for arsenite; [39]) and pyruvate dehydroge-
nase (PDH IC50: 80–120μM arsenite; [40]), relatively large
concentrations were required to inhibit these enzymes. In
fact, arsenate has been shown to stimulate the activities of
the two important glycolytic enzymes, hexokinase [37]a n d
GAPDH [41], by overcoming product inhibition in these re-
actions. In the case of GAPDH, arsenate acts catalytically to
promote the oxidation of phosphoglycerate [42] and the re-
action involved the formation of an arsenate analogue of the
phosphateesterasanintermediatewhichrapidlyhydrolysed,
helping to drive the reaction forward [33, 43]. This process
has been commonly described in relation to the eﬀects of
arsenate on numerous enzymatic reactions involving phos-
phate and has been termed “arsenolysis” [33].
Given the relative insensitivity to the direct eﬀects of ar-
senic compounds shown by the glycolytic pathway, it follows
that it is unlikely that glycolytic inhibition results from di-
rect binding and modiﬁcation of the enzymes in this path-
way by arsenic-based drugs. More likely, the inhibition of
glycolysis results from an indirect eﬀect, caused by the ac-
tions of arsenic compounds in modifying mitochondrial res-
piration leading to production of ROS which then acts to
inhibit the glycolytic enzymes. Additional support for the
mitochondrial-mediated ROS involvement in the action of
arsenic to inhibit glycolysis comes from studies where As2O3
was found to be ∼38 times more potent in cells than in
the pure preparation at inhibiting pyruvate dehydrogenase
[40]. Also, inhibiting mitochondrial respiration suppressed
the resulting inhibition of pyruvate dehydrogenase activity
and H2O2 production by this drug. Furthermore, the inhibi-
tion of pyruvate dehydrogenase by As2O3 was shown to re-
quire the Fenton reaction occurring via hydroxyl radical in-
termediates [40]. The mitochondrial eﬀects of arsenic com-
pounds are detailed later in this review and to reiterate at this
point, the evidence indicates that the actions of arsenic com-
pounds on glycolysis are not the main cause for the cytotoxic
eﬀects of these drugs at clinically relevant concentrations (1–
6μM)requiredinplasmaforthekillingofcancercellsinAPL
patients [8, 44].
3.2. InterconversionofAs(III)←→ As(V)incells
Under conditions of high mitochondrial respiration inside
cells, it is possible that trivalent arsenicals inducing signif-
icant production of ROS as superoxide, peroxide, and hy-
droxyl radicals can also result in oxidation to produce arsen-
ate(AsO4
3−)ionicspecies[45,46].Consequently,theimpact
that arsenic compounds will have on any given cell will most
likely depend on the state of cellular respiration and pro-
duction of ROS aﬀecting the arsenic speciation and whether
the cell is dependant on glycolysis versus mitochondrial res-
piration for its ATP synthesis. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), the glycolytic enzyme abundantly
found in all cells and especially blood cells and liver, is a
major intracellular arsenate reductase [47] requiring GSH,
NAD, and glycolytic substrate [48, 49]. Given that the levels
and speciﬁc activity of GAPDH is much higher in malignant
cells than in normal cells [50], this could contribute to the
rapid reduction of As(V) species in their cytosol into more
toxic As(III) forms.
In the GAPDH reaction, As(V) reduction may take place
during, or as a consequence of the arsenolytic cleavage of
the thioester bond formed between the enzyme’s Cys149
residue and the 3-phosphoglyceroyl moiety of the substrate.
Hydrolysis of 1-arseno-3-phosphoglycerate is at least 2000
times faster than hydrolysis of the normal substrate 1,3-
diphosphoglycerate under the same conditions [51]. Hence,
GAPDH is proposed as one of the key cellular converting en-
zymes for reducing As(V) to As(III). Although purine nu-
cleoside phosphorylase was proposed to be an arsenate re-
ductase [52], this was later refuted [53]. The other major
class of As(V) reductases in cells are the glutathione S trans-
ferases and of these, the omega form or GSTO1 appears to
be most important. Thus, GSTO1 can reduce arsenate to ar-
senite, MMA(V) to MMA(III), and DMA(V) to DMA(III)
and deletion of the GSTO1 gene in mice reduced the ex-
tent of biotransformation by 30–80% in most tissues exam-
ined [54].
3.3. Structureandreactivityofarsenic-containing
compoundswithreducedthiols
Arsenic has a high aﬃnity for sulfur and hence, reactive
sulfur-containing molecules such as reduced thiols with an
available sulfur atom have a signiﬁcant propensity for bind-
ing to arsenic [55, 56]. As(III)-containing compounds exist
as trigonal pyramidal structures and this is also the structure
formed upon binding of arsenic ions to cellular proteins in
vivo where the sulphur atoms of thiolate groups act as co-
ordinating ligands. The resulting arsenic-thiol linkages are
mainly responsible for the ability of arsenic to modulate the
function of various key molecules, enzymes, and ion trans-
porters inside cells and this intracellular action of arsenic is
discussed in detail in this section. Arsenic-containing com-
pounds react with mono- and dithiols, particularly the lat-
ter when two thiols are located in close proximity, acting to
cross-link the thiols together.
Some debate exists about the structures and speciation of
arsenic-containing compounds (both inorganic and organic
forms) in solution. In the absence of sulﬁde, As(III) hydrox-
ide complexes are the major arsenic-containing species and
these structures probably adopt a trigonal pyramidal struc-
ture with the arsenic atom at the apex [57–59]. This trigonal
pyramidal structure provides the potential for As(III) to co-
ordinate linkages with several proximal thiol groups. This is
believed to be the case in bacterial enzyme systems such as
the ArsR repressor protein where it is likely to bind three Cys
atoms[60].Thus,inthemoretoxicformasthetrivalentstate
(As(III)) inorganic and organic (methylated) arsenic reacts
with critical thiols in proteins, inhibiting their function, as is
the case with the bacterial ArsR protein. For example, As(III)
wasshowntotargetthereactivesulfhydrylgroupattheactive
site of thiolase(s) involved in ketogenesis from acetyl Coen-
z y m eA[ 61].
The pentavalent species of inorganic arsenate (AsO4
3−)
favoured to exist in oxidised environments, as well as organic
forms of As(V) have a diﬀerent structure with a trigonal-
bipyramidal shape where the As(V) atom is located at theS t e p h e nJ o h nR a l p h 5
centre,co-ordinatingtothreeequatorialandtwopolaratoms
[62, 63]. In comparing the two diﬀerent structural states
of As(III) and As(V), it is not yet clear why the trivalent
methylarsenic-containing compounds show a much higher
toxicity than their pentavalent analogues [24, 64]. However,
it could relate to cellular uptake as trivalent organoarsenic
compounds are more membrane permeable than the pen-
tavalent species [65]. Also, trivalent arsenic bonded at a
phenyl ring is able to form much more stable covalent
cross-links to cysteine residues compared to arsenic in small
molecules such as arsenious acid or arsenite [66]. Further-
more, the organic trivalent arsenic-containing compound,
phenylarsine oxide [0.1–0.5μM], is much more potent than
the simple arsenite [1–10μM] in its cytotoxic activity in APL
cells [67].
One major drawback with phenylarsine oxide as a poten-
tial cancer therapy is its high toxicity in vivo and its nonse-
lectivity for cancer versus normal cells, resulting in cytotox-
icity in normal endothelial cells in the same concentration
range (0.2μM) [68]. Thus, phenylarsine oxide, is precluded
from application in clinical cancer therapy, without being
further modiﬁed as a drug. The greater reactivity of pheny-
larsene oxide and associated cytotoxicity is in agreement
with the results outlined above [66] where mass spectromet-
ric analysis of diﬀerent complexes of peptides and proteins
with arsenic-containing species revealed that inorganic ar-
senite or arsenates did not interact well with cysteine or glu-
tathione,whereastheorganicphenylarsine(3+)oxidedid.In
addition, three diﬀerent phenyl arsenic acids and dimethy-
larsinic acid that all contained As(V) also formed complexes
with glutathione [66]. Hence, the bulky hydrophobic groups
with electron withdrawing π orbitals (in the case of phenyl
groups) may promote more stable bonds between the ar-
senicatomandsulfurgroupsinsidecells,modulatingalarger
range of enzymes and proteins with important functions for
maintaining cell viability.
In cells, the most common reactive species that are avail-
able for interaction with arsenic are the abundant free thiol
moieties in the tripeptide glutathione (γGlu-Cys-Gly, GSH)
and the free amino acid, cysteine. Thus, arsenic-based drugs
can react by coordinating binding to free (reduced) thiol
groupssuchasthoseoncysteine,particularlythoseofthiore-
doxin and glutathione as the major intracellular thiol species
important in cellular redox regulation. It was observed early
on that arsenite and phenylarsine oxide in particular, but
not arsenate, reacted with vicinal thiol groups on proteins
[69, 70]. Since demonstrating that phenylarsine oxide was
particularly eﬀective at cross-linking vicinal thiols in the ac-
tive site of tyrosine phosphatases [71], the range of proteins
-containing vicinal cysteine residues with which phenylar-
sine oxide reacts is increasing. Recent examples include the
small GTP binding Rho protein family [72] and the mito-
chondrial carnitine/acylcarnitine transporter [73]. Phenylar-
sine oxide, as a strong inhibitor of tyrosine phosphatases
would increase tyrosine phosphorylation levels of enzymes
in cellular growth signalling pathways. Whether the inhibi-
tion of tyrosine phosphatases and other enzymes contributes
to the toxic eﬀects of arsenic-containing compounds in nor-
mal cells is not clear, but is likely an important contributing
factor to its general cytotoxicity making phenylarsine oxide
unsuitable for cancer therapy.
Analysis of the interactions of As(III) with glutathione or
cysteineinvitroinaqueoussolutionsbyequilibriumbinding
and use of biophysical techniques including NMR, electronic
spectroscopy, and potentiometry revealed that As(III) binds
either of glutathione or cysteine with similar equilibrium
constants [74]. However, several analytical studies by mass
spectroscopy have revealed that arsenate and arsenite do not
complex readily with glutathione or cysteine, but prefer to
react with the thiols on reduced thioredoxin molecules [re-
viewed in [66]]. This was conﬁrmed by analysis of more bio-
logicallyrelevantsamplesfromtheintracellularenvironment
of HeLa cells where cytosolic thioredoxin 1 (TRX1) and, in
particular thioredoxin 2 (TRX2) in the mitochondria, was
shown to be highly reactive with arsenite (10μM) whereas
little reactivity was detected with cellular GSH/GSSG [75].
Studies with thioredoxin reductase (TxR) puriﬁed from
mouselivershowedthatarsenic-containingcompoundswith
As(III) and arsinothiols (complexes of As(III) with GSH
or L-cysteine) were extremely potent inhibitors of this en-
zyme [24]. Methylarsenic(III)oxide was most potent with a
Ki∼100nM, as an irreversible competitive inhibitor. The ef-
fects on puriﬁed glutathione reductase (GR) showed that
the levels of inhibition were not as marked with inorganic
As(III) and As(V) oxides showing IC50s in the 10–50mM
range, whereas for methylarsinic(III)oxide it was ∼9μM.
Studies on this enzyme in whole cells as hepatocytes showed
the IC50 to be reduced to ∼3μM for methylarsinic(III) ox-
ide and for As2O3 > 100 μM[ 24]. Hence, these observations
strongly support a role for the components thioredoxins and
thethioredoxinreductasesystemasprovidingcellulartargets
that are very sensitive to inhibition by arsenic-based drugs in
the low micromolar range. It also explains the importance of
studying the chemistry of arsenic-containing compounds in
the context of both puriﬁed enzymes as well as whole cells
as biological systems in order to obtain meaningful results.
Thus, although the GSH/glutathione transferase system un-
doubtedly plays an important role in arsenic sensitivity of
c e l l s( s e eb e l o wi nSection 4 for details), it would appear that
the thioredoxin system might represent the most immediate
point of sensitive reactivity in relation to cytotoxicity.
3.4. Themajormechanismofactionof
arsenic-containingcompounds:modifying
mitochondrialfunctionandredoxregulation
oftheproductionofreactiveoxygenspecies
Mitochondria are a main source of ROS in cells (reviewed in
[76]). Thioredoxin (TRX), NADPH, and thioredoxin reduc-
tase (TxR) comprise the thioredoxin system that has mul-
tiple functions in cells including in redox signalling via in-
teractions with other proteins, in transcriptional regulation,
control of the reduced intracellular redox environment, cell
growth, defense against oxidative stress and control of apop-
tosis (reviewed in [77]). As outlined in the previous sec-
tion, the thioredoxin system is very sensitive to arsenic-based
drugs and may well be the basis for one of the important
mechanisms for their actions in inducing cancer cell death.6 Metal-Based Drugs
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Figure 1: Many vicinal thiol-containing redox proteins are major mitochondrial targets for binding of arsenic-containing compounds. Arsenite
and particularly organic arsenites will disrupt the normal redox systems functioning in the mitochondrial matrix and intermembrane space
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2 (Trx2). In addition, several key mitochondrial functions are aﬀected, including Factor B regulating the ATP synthetase activity, the adenine
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The TRX system operates as a thiol-disulﬁde exchange re-
action (see Figure 1). TRX1 and TRX2 are key regulatory
isozymes that catalyse the reduction of protein disulﬁde
bonds. They are cofactors of the apoptosis signal-regulating
kinase 1 (ASK1) that mediates TNF cytokine and oxidative
stress-induced apoptosis via the mitochondrial dependent
pathway [78].
In their reduced forms, cytosolic TRX1 and mitochon-
drial TRX2 each contain two vicinal thiol groups in their
active site sequence as –C–G–P–C–. TRX 1 in the cytosol
and TRX2 in mitochondria bind to Cys 250 and Cys 30, re-
spectively, in the regulatory N-terminal domain of ASK1 and
can cooperatively maintain the enzyme in the inhibited state.
However, activation by TNF resulting in increased produc-
tion of ROS and leads to the oxidation of the TRX dithiol
group to a disulﬁde. Under these conditions, the thioredox-
ins no longer bind to ASK1 and loss of TRX2 binding to
mitochondrial-located ASK1 can lead to apoptosis in a JNK-
independent manner, whereas cytosolic ASK1 upon loss of
TRX1 binding then becomes activated as a MAPKKK result-
ing in JNK activation, Bid cleavage and Bax translocation to
the mitochondria [78]. Since it is known that the thioredox-
ins are major targets of arsenic-containing compounds (see
above and [75]), it can be predicted that arsenite-mediated
oxidative binding to thioredoxins will induce a similar out-
come as TNF signalling, leading to the release and activation
of ASK1 and induction of apoptosis.
Anotherthioredoxin-associated proteinof importance in
thiol-mediated redox regulation in mitochondria is thiore-
doxin peroxidase II (TPX-II, also known as peroxiredoxin
III, Prx-III), an enzyme abundantly expressed in the mito-
chondria of cancer cells that protects the cells from oxida-
tive stress [79, 80]. PrxIII is an important antioxidant that
acts in conjunction with TRX2/TXR (Figure 1) in the mito-
chondria to remove peroxides such as H2O2 and oﬀset the
apoptosis inducing eﬀects of increased levels of H2O2.H o w -
ever, PrxIII contains three Cys residues, two of which are in-
volved as redox-active sites in the formation of a stable in-
tersubunit disulﬁde-bonded dimer, which is then reduced
by thioredoxin to the monomer. PrxIII was a more abun-
dantly expressed arsenic-binding protein when comparing
arsenic resistant cells to normal cells by phenylarsine oxide
aﬃnity chromatography [81]. Hence, PrxIII is very likely to
be another protein whose function is inhibited by arsenic-
containing compounds leading to the promotion of apopto-
sis.
Increasingly, it is becoming apparent that dithiols-
containing redox proteins, particularly those present in the
mitochondria, act as controlling sensors during responses to
changes in cellular redox. Many thiol redox proteins con-
tain a vicinal pair or more of reactive thiol groups [82, 83]
capable of binding with arsenic-containing compounds in
a similar manner to those in the thioredoxin system. The
most important of these are located in the mitochondria,S t e p h e nJ o h nR a l p h 7
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Figure 2: Mitochondrial redox systems regulating ROS levels via
thiol-disulﬁde exchange/coupling reactions. The mitochondrial form
of Thioredoxin (Trx2) is likely to play the major role in reducing
disulﬁdes formed by vicinal thiols in both the mitochondrial Perox-
iredoxin III (Prx III) and other proteins. Prx III is one of the main
ways by which cancer cells can reduce their levels of H2O2 built up
during active respiration. The glutathione redox system comprising
GSH/GSSG, glutathione reductase, glutaredoxin, and glutathione
peroxidase, although present in the mitochondria, is more likely to
only become of major importance during the more extreme condi-
tions of oxidative stress. Both of these systems are targets for inhibi-
tion by arsenic-containing compounds. See text for further detail.
a point of extreme sensitivity to arsenic-containing com-
pounds whose actions culminate in triggering the apoptotic
pathwaysviatheinductionofreactiveoxygenspecies,leading
to the killing of the cancer cells (Figures 1, 2). For example,
two members of the glutaredoxin (GRX) family, including
GRX2 located primarily in the mitochondria, catalyse GSH-
dependent TRX-disulﬁde redox and protein thiol-disulﬁde
redox reactions, particularly reversible glutathionylation of
protein sulfhydryl groups [84]. Human Grx1 and Grx2 con-
tain C–P–Y–C and C–S–Y–C active sites ; have three and
two additional structural Cys residues, respectively; and are
therefore likely to react with arsenic-containing compounds,
although no reports of this could be found.
Another mitochondrial protein targeted by arsenic-
containing compounds with a vicinal dithiol group is reg-
ulatory protein “Factor B.” Addition of recombinant factor
B back to bovine submitochondrial particles depleted of this
protein restored energy coupling activity. Thus, reverse elec-
tron transfer from succinate to complex I enabling NAD+
reduction, electron transport chain function and oxidative
phosphorylation/32Pi-ATP exchange of the ATP synthetase
complex were reactivated [85] as was increased exchange ac-
tivity of complex V [86]. Thus, the F0-F1 ATPase activity re-
quires Factor B coupled to it for full activation. However,
factor B contains six thiols and Cys 92 and Cys 94 in the
bovineformwereshowntobindphenylarsineoxide[87]and
phenylarsine oxide or arsenite inhibit factor B coupling ac-
tivity [88]. From all of these studies, it is becoming clear that
redox changes to vicinal thiols aﬀect the regulation of mito-
chondrialfunctionandthatthesethiolsarealsomajortargets
forinhibition bythe arsenic-containing compounds (Figures
1, 2).
4. THE ADENINE NUCLEOTIDE TRANSPORTER (ANT):
A CRITICAL TARGET OF ARSENIC-CONTAINING
COMPOUNDS IN THE MITOCHONDRIA
A channel formed by the association of two proteins, the
voltage dependent anion channel (VDAC) in the outer mito-
chondrial membrane and the adenine nucleotide transporter
(ANT) in the inner mitochondrial membrane (Figure 1), is
a complex involved in the induction of apoptosis activated
via the mitochondrial pathway (see [89,F i g u r e3 ] ) .T h et w o
components of this complex form part of the mitochondrial
permeability transition pore (MPTP), a megachannel medi-
ating release of molecules from the mitochondria activating
apoptosis. A rapidly increased permeability of the inner mi-
tochondrial membrane (mitochondrial permeability transi-
tion) leads to apoptosis that is mediated by the MPTP.
ArseniteinducesapoptosisbyadirecteﬀectontheMPTP
[90, 91] and VDAC has been shown to play an essential role
in opening of the permeability pore and cytochrome c re-
lease induced by arsenic trioxide, which also caused VDAC
to homodimerise [92]. In addition, the thiol-reactive com-
pound 4,4’-diisothiocyanostilbene-2,2’-disulfonate (DIDS)
has been shown to block the VDAC channel [93] and inhibit
ROS-mediated cytochrome c release by VDAC [94]. Hence,
the data indicates that VDAC contains critical Cys residues
that can undergo intermolecular cross-links mediated by re-
action with arsenic.
Analysis of ion channel activity of puriﬁed ANT-
containing lipid bilayers also revealed that As2O3 treatment
[30μM] altered the ANT channel electrophysiological prop-
erties [36]. Interestingly, glutathione depletion leading to in-
creased ROS may play an important role in the action of
arsenic trioxide [91]. Whereas in both normal and cancer
cells, glutathione S transferase (GST) is found to interact
with ANT, during the induction phase of apoptosis, GST dis-
sociates from ANT suggesting that GST/GSH may act as a
repressor of MPTP and ANT pore opening [91, 95]. This is
supported by the observation that increasing the expression
of the enzyme GSTP1 in Jurkat and Raji leukemic cells ren-
ders them more resistant to arsenic trioxide-induced apop-
tosis at clinically relevant levels [1-2μM]. GSTP1 expression
in these cells is also accompanied by accumulation of lower
levels of H2O2 production [95].
Both of the mammalian proteins, VDAC and ANT, con-
tain two or more Cys residues in their structure thereby pro-
viding reactive thiol groups whose modiﬁcation aﬀects their
function. It has been established that the redox state of thiol
reactivegroupsareimportantforactivationofthemitochon-
drialpermeabilitytransition[94,96,97].Consequently,thiol
cross-linkers such as DIDS, diamide, and phenylarsine ox-
ide [20–100μM] aﬀect VDAC and ANT channel function
and activation of mitochondrial permeability transition [93,
94, 96–98]. Many published results, such as cross-linking ex-
periments,protein/inhibitorstoichiometry,chimericdimers,
analytical ultracentrifugation, or neutron scattering, indi-
cate that the ANT carrier acts as a dimer and this or higher
oligomers are involved in membrane permeability transition
[99, 100].8 Metal-Based Drugs
Facing out into the mitochondrial matrix, ANT has three
exposedloopregionscontainingaconservedrepeatstructure
with one Cys residue in each loop. These Cys residues are
important to the process of ANT dimerisation, but it is not
clear how this operates and whether the Cys residues form
intermolecular disulﬁde bonds or not [101]. Nevertheless,
copper-o-phenanthroline is able to dimerise ANT by inter-
molecular cross-linking of Cys 56 (in the ﬁrst matrix loop)
[98]. In addition, phenylarsine oxide, eosin 5-maleimide,
and diamide form intramolecular cross-links between Cys
160 and Cys 257 on the other two matrix loops, restricting
ANT in the open conformation, promoting mitochondrial
permeabilitytransition[98].Arsenictrioxideismuchweaker
than phenylarsine oxide at binding to the ANT Cys residues
[96, 97] and this may explain the greater sensitivity exhib-
ited by APL cells to phenylarsine oxide [IC50: 0.1μM] than
to As2O3 [IC50: 4μM] [67].
Single thiol interacting compounds such as N-
ethylmaleimide (NEM) can inhibit the mitochondrial
permeability transition and this could be either the result of
direct interaction with the key Cys residues on the matrix
loops of ANT or indirectly via reaction with GSH and
thereby preventing GSH from being oxidized and catalysing
disulﬁde bridging between the adjacent thiol groups in
the ANT loops [98]. NEM or monobromobimane, in the
25–50μM range, preferentially react with GSH, leading
to its modiﬁcation in mitochondria and thereby prevents
GSH from being oxidised. As a result, NEM inhibits mi-
tochondrial permeability transition activation by the thiol
reactive compounds, diamide or t-butylhydroperoxide,
implying a role for GSSG in the action of these agents on the
permeability transition [96, 97]. Arsenites, albeit that much
higher concentrations would be required given their lower
aﬃnity for glutathione interaction, could have a similar
action. Thus, high levels of arsenites could modify and in-
hibit glutathione redox control such that glutathione-based
enzymes are unable to function, as well as directly mediating
disulﬁde cross-linking of ANT, leading to increases in cellu-
lar ROS production, MPTP, and apoptosis. However, given
their low reactivity with glutathione systems, this appears
to be unlikely as opposed to the indirect action via the
mitochondrial eﬀects leading to increased ROS production
which then reduces cellular GSH levels.
The multidrug resistance (MDR) protein MRP1/ABCC1
has been shown to transport AsIII out of cells as a tri-GSH
conjugate(As-(GSH)3),andglutathioneS-transferase(GST)
probably facilitates the process [102]. This is likely to be part
of the normal cell and cancer cell resistance mechanisms
against the cytotoxic eﬀects of arsenic-based compounds.
GSH-depleted cells are more sensitive to killing by arsenic-
containing compounds [103] and transfection of cells to ex-
press glutathione S transferase protects them from arsenite
inducing death by promoting arsenite transport from the
cells and decreasing ROS levels [104, 105]. In support of
this proposal, the long-term exposure of cells to arsenic-
containing compounds induced increased expression of glu-
tathione S transferase and MRPs [106]. Arsenic levels do not
attain very high levels in blood plasma of patients, rapidly
becoming eliminated [8, 44, 107]. This removal probably re-
sults from eﬃcient uptake of As-(GSH)3 via MRP2 in the
proximal tubules of the kidneys as part of the detoxiﬁcation
process during the excretion of arsenic-based drugs predom-
inantlyintotheurine [108,109].Theremainderis mostlyre-
movedviauptakeintheliverandsecretionasbile[110–112].
As-(GSH)3 may be an important part of the metabolic pro-
cess for converting inorganic As(III) to methylated species
during detoxiﬁcation in the liver by ASMT1/Cyt19 [113].
5. MODIFIED ORGANIC ARSENIC
STRUCTURES WITH INCREASED POTENCY
AS ANTINEOPLASTIC AGENTS
Arsenic-containing compounds substituted with organic
groups such as modiﬁed phenylarsine oxides have been syn-
thesized and examined for their cytotoxic eﬀect on human
leukemic cells and breast cancer cells in culture. Some of
these compounds were found to exhibit potent cytotoxic an-
ticancer activity, particularly against human breast cancer
and leukemic cell lines, including primary leukemia cells,
at micromolar concentrations. One of these compounds,
the novel glutathionyl peptide trivalent arsenic-containing
compound para 4-[N-(S-glutathionylacetyl)amino]pheny-
larsenoxide(p-GSAO)showspromiseasanovelantineoplas-
tic drug and is now in clinical trials. P-GSAO, like pheny-
larsine oxide, inactivates ANT-mediated ATP/ADP trans-
port and triggers Ca2+-dependent MPTP opening by cross-
linking the critical Cys residues of ANT. This leads to in-
creased production of cellular ROS, ATP depletion, mito-
chondrial depolarization, and apoptosis of angiogenic en-
dothelial cells and inhibition of tumor growth in mice with
no apparent toxicity [114]. However, the action of p-GSAO
was indirect, and did not appear to be as a result of selective
tumor cell toxicity. Rather, p-GSAO inhibited the proliferat-
ing, but not growth-quiescent endothelial cells in vitro and
angiogenesis in vivo and thus acted to eliminate tumors by
blocking theirbloodsupply[114,115].Thetrivalentarsenic-
containing moiety of p-GSAO was shown to cross-link the
matrixfacingCys160andCys257thiolsofANT[114]andef-
fectivelylocksANTintotheopenconﬁguration.Inactivation
of ANT by p-GSAO causes an increase in superoxide levels,
proliferation arrest, ATP depletion, mitochondrial depolar-
ization, and apoptosis in the dividing endothelial cells.
It is likely that the arsenic-containing moiety of p-GSAO
reacts similarly as does arsenite (see above) with one or two
molecules of glutathione before it is removed from the cell
by MRPs [116]. Tumor cells export p-GSAO much more eﬃ-
ciently than endothelial cells because they have higher MRP1
or MRP2 activity and cellular glutathione levels [116]a n d
this may explain why p-GSAO is not highly eﬀective at in-
hibiting tumor cell growth in vivo. In addition, the greater
water soluble properties of p-GSAO than other arsenic-
containing compounds, particularly organic species should
help to retain p-GSAO in the intravascular system where it is
more likely to aﬀect endothelial cells and inhibit tumor an-
giogenesis.
Interestingly, although the para form of GSAO revealed
no apparent toxicity in treated animals and inhibited tumor
growthleadingtophaseIclinicaltrialsasananticanceragentS t e p h e nJ o h nR a l p h 9
[114], the ortho form (o-GSAO) was toxic and this was pro-
posed to result from increased accumulation of the drug in
cells, including normal cells due to loss of multidrug resis-
tance eﬄux [116]. Consequently, o-GSAO is unlikely to be of
much further interest as an antineoplastic agent, whereas the
clinical eﬃcacy of p-GSAO is eagerly awaited.
6. TARGETING OF CANCER CELLS: SELECTIVE
UPTAKE AND DELIVERY INTO SPECIFIC TYPES
OF CANCER CELLS
As(III) as the anhydrous form of As(OH)3 (Trisenox, Cell
Therapeutics, Seattle, Wash, USA) received FDA approval
in 2000 as a chemotherapeutic agent for the treatment of
APL [117]. Acute promyelocytic leukemia (APL) is associ-
ated with reciprocal and balanced chromosomal transloca-
tions always involving the retinoic acid receptor alpha (RAR-
alpha) gene on chromosome 17 and variable partner genes
on distinct chromosomes. RARalpha fuses to the promyeloc-
tyic leukemia (PML) gene in the majority of APL cases (re-
viewed in [118]). Arsenic trioxide is particularly eﬀective at
killing APL cells and this was proposed to be the direct result
of its ability to induce the relocalization and degradation of
the nuclear body protein PML, as well as the degradation of
PML-RARalpha in APL cells [119–122]. However, this seems
unlikely to be the main mechanism of action for arsenic tri-
oxide given that no diﬀerences in sensitivity to growth inhi-
bition and killing by apoptosis have been observed between
wild-type and PML−/− cells [123].
Arsenic trioxide as a single agent has provided 86% com-
plete hematologic remission with minimal toxicity in APL
patients [124], equal to any of the current standards of
care for treating APL, including the combination of all-trans
retinoic acid (ATRA) plus chemotherapy [125]. This raises
the question why APL cells are very sensitive to arsenic-
containing compounds like arsenic trioxide. It would appear
that the reason is because APL cells express the transmem-
brane transporter protein, aquaglyceroporin 9 (AQP9) in-
volved in arsenic uptake [126]a tm u c hh i g h e rl e v e l si nA P L
cellsthaninotherleukemiccelltypesandthatcorrelateswith
arsenite sensitivity [127]. In this regard, it is worth noting
that aquaglyceroporins AQP7 and AQP9 are present in nor-
mal cell types. Interestingly, AQP9 is primarily expressed in
human lung, liver, and leukocytes [128] and this may help
explain arsenic toxicity, given that liver is one of the main or-
gans aﬀected. The fact that AQP9 provides APL cancer cell
speciﬁcity with high response rates suggests that if arsenic-
containing compounds could be targeted for speciﬁc deliv-
ery into cancer cells, then they would represent outstanding
agents for killing these cells. However, further modiﬁcations
will be required to provide suitable drug targeting for im-
proved delivery of arsenic-containing compounds to cancer
cells.
7. CONCLUSIONS
Vicinal thiols located in key enzymes and proteins provide
targetsforreactionwitharsenic-containingcompounds,par-
ticularly organic derivatives such as phenylarsenic-contain-
ing compounds that favour intramolecular cross-linking be-
tween adjacent thiols. Intriguingly, most of the key intra-
cellular targets for this reaction have been identiﬁed to in-
clude the main REDOX regulatory systems in the mitochon-
dria, including thioredoxin and peroxiredoxin systems and
the adenine nucleotide transporter, all of whose function is
adversely aﬀected. The net result is the activation of sev-
eral independent pathways including ROS production to fa-
cilitate the induction of apoptosis. One main pathway op-
erates via the opening of the MPTP, the other via activa-
tion of ASK1 kinase, and the JNK/Bid/Bax pathway of chan-
nel formation in MOM. In the case of APL, cell selectiv-
ity for sensitive responses to these drugs is facilitated by
selective transport systems such as provided by the AQP9
transporter. Low MDR levels present in dividing endothelial
cells also provides selective targeting by specially substituted
phenylarsenic-containing compounds like p-GSAO, leading
to decreased blood supply into tumors, with some toxicity to
cancer cells, but little toxicity on normal cells. Hence, a com-
bination of selective delivery and retention provides the nec-
essary targeting of arsenic-containing compounds to tumors
and provides scope for additional modiﬁcations to be made
to enhance the antineoplastic activity of arsenic-containing
compounds, given their range of actions and eﬃciency in
killing cancer cells.
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